Develop orally administered treatments for diabetes. Develop orally administered treatments for inflammatory diseases. Now — the numbers.
The company is still in the product-building phase: its spending runs far above its sales. That only changes once the product starts selling at scale.
Red columns mark years that ended in a loss.
At this burn rate the cash pile isn’t the pressing question — for now, time is on the company’s side.
Executives buying with their own money is usually read as confidence in the company’s future.
We compared this company with its own sector across five subjects.
A score of 50 means class average.
Clearly above the class average — a step short of the very top.
Clearly below the class average.
Clearly above the class average — a step short of the very top.
Clearly below the class average.
The price is looking for direction — no strong breakout, no collapse.
Growth: Sales growth trails the sector average.
Financial Strength: The cash-and-debt balance is thin; the buffer for hard times is slim.
The stock trades 53% below its peak. The market has trimmed its expectations for the company.
There is $88.9M in the vault; even if every debt were paid off, $88.9M would remain.
Over the last 12 months, company executives reported 20 buys and 0 sells. Management buying with its own money is usually read as a good sign.
A loss of $27.0M against $0 in annual sales. And on top of that, sales fell from the year before.
The growth engine is running at low revs right now. Report-card grade: 9/100.
The balance sheet offers little cushion against a rough stretch. Report-card grade: 45/100.
On our five-subject report card, VTVT sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”
The takeaway: VTVT is a high-risk stock — not yet profitable, and its future rides on its product catching on.
The total grade weighs these five subjects against the sector — it isn’t a simple average of the five.
Not covered, because the filings we hold do not carry it: the revenue breakdown.